

Corres. and Mail  
**BOX AF**

AF/1600

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on

Attorney Docket No. 9950-0002  
PATENT

February 19, 2002  
9 Feb 2002  
Date  
Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPERS  
ORIGINAL FILED  
RECEIVED  
MAR 19 2002  
TECH CENTER 1600/2000

In Re Application of:  
ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: P. Huynh

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents,  
Washington, DC 20231

Sir:

Transmitted herewith for filing is an amendment in the above patent application in response to the Office Action of December 18, 2001.

  X   Also enclosed: Return Post Card.

  X   No additional amendment fee is required.

No. of Claims After Amendment		Most Claims Previously Paid		Extra Claims				Additional Fee
A. Total Claims	5	-	20	=	0	x	\$18	= 0.00
B. Ind. Claims	1	-	4	=	0	x	\$84	= 0.00
C. If amended to contain multiple dependent claims, add \$280							\$280	= 0.00
D. Total Amendment Fee (Total of A, B & C)								= 0.00
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								= 0.00
F. Total Amendment Fee (D minus E)								= 0.00

The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

By:

  
J. Elin Hartrum

Registration No. 43,663

REED & ASSOCIATES  
800 Menlo Avenue, Suite 210  
Menlo Park, California 94025  
(650) 330-0900 Telephone  
(650) 330-0980 Facsimile

F:\Document\9950\0002\Amend 1.116 xtl.wpd

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

Attorney Docket No. 9950-0002  
Serial No. 09/402,273

Date: February 19, 2002 Signature: [Signature]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:  
ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: P. Huynh

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

**AMENDMENT UNDER 37 CFR § 1.116**  
**EXPEDITED PROCEDURE: GROUP ART UNIT 1644**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the final Office Action in the above-identified case, mailed on December 18, 2001. Reconsideration of the application in view of the following remarks and amendments is respectfully requested.

**AMENDMENTS**

**IN THE CLAIMS:**

Please amend claim 1 as indicated in Appendix A. The amended claim reads as follows:

1. (Twice Amended) A pharmaceutical composition capable of selectively enhancing a TH<sub>1</sub> response comprising tyrosine, an allergen or allergen extract, optionally modified by reaction with a cross-linking agent, and 3-DMPL.